News

Piatek discussed findings from a healthcare resource utilization study and a sentiment analysis study presented at ASH 2024.

New topline data released by Inmagene indicate positive findings from a phase 2a trial on IMG-007 for moderate-to-severe atopic dermatitis.

Additional TEASE-3 participants who completed 24 months of gildeuretinol therapy reported no progression in Stargardt disease, including stable visual acuity.

In this analysis, investigators highlighted various disease-related views and experiences dermatologists may wish to consider among Latine patients with psoriasis.

After accepting the avacincaptad pegol sNDA on January 6, 2025, the FDA has set a target action date for February 26.

Individuals with stable schizophrenia struggle to recognize facial emotions such as sadness, disgust, and anger—but not happiness—which may impact social interactions.

Findings from the HOPE Consortium Trial suggest PCST can help pain interference and quality of life in patients on hemodialysis experiencing chronic pain.

Study findings highlight increasing rates of AH among adolescents and younger adults, with women facing worse long-term liver-related outcomes.

An economic analysis highlights a cardiovascular polypill's potential to lower healthcare costs and address income-based health disparities.

A study found long-acting injectables reduced mean Young Mania Rating Scales scores in adolescents with bipolar mania from 33.8 at baseline to 21.7 at month 1.

From 2000 to 2021, primary liver cancer incidences and deaths in the US increased by more than 100%, driven by rapid growth in ALD and MASLD.

The biosimilars month in review highlights a newly approved ustekinumab biosimilar and a look into the field in 2024.

Phase 2 data demonstrates the effectiveness of LB-102, developed with the potential to be the first-in-class benzamide antipsychotic, for adults with acute schizophrenia.

This analysis using worldwide data from GBD 2021 indicates that the global burden of eczema in children has gradually risen and has been projected to continue increasing.

The designation follows positive topline data from the phase 2a trial of CNP-104 in PBC, which were presented at AASLD’s The Liver Meeting

This Month in Review captures 7 sleep medicine news, including FDA updates, from December 2024.

The month in review features coverage of renal pipeline updates, a new nephrology podcast episode, and recent research in IgAN and FSGS.

CT-P42 may help improve access to aflibercept in lower-income countries.

Hyperuricemia was significantly linked to dyslipidemia and hypertriglyceridemia in hospitalized patients with type 2 diabetes, which remained after adjustment.

These data shed light on the association between parental age at the time of delivery and development of 6 allergic diseases.

A study found intimate partner violence significantly lowers women's psychosocial well-being across finances, health, and relationships, but not men's.

Study findings suggest outcomes observed with intensive blood pressure targets in SPRINT are transportable to patients with CKD in clinical practice.

Variations in apoB concentration among Hispanic or Latino populations could provide important implications for apoB use in cardiovascular risk assessment.

In this analysis, a retrospective and multi-center study was conducted to determine any predictors of biological therapy intensification in individuals with HS.

Participants with greater vitamin D levels had a 16% lower migraine prevalence than those with lower vitamin D levels.

Findings suggest the potential value of anti-gliadin and anti-F-actin IgA for risk stratification in patients with primary sclerosing cholangitis.

This analysis highlights the connection between organic food consumption and respiratory/allergic morbidity among those of school age.

Glutamatergic medications show promise for OCD & related disorders, reducing Y-BOCS scores.